Sepsis Diagnostics Market Size & Share | Statistics Report 2028
The sepsis diagnostics market is projected to reach US$ 1,226.52 million by 2028 from US$ 661.83 million in 2021; it is expected to grow at a CAGR of 9.2% from 2021 to 2028.
Factors such as the surging incidence of sepsis due to increasing nosocomial infections and rising demand for rapid diagnostic tests leading to increasing product launches drive the sepsis diagnostics market growth.
Sepsis is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. Three stages of sepsis are sepsis, severe sepsis, and the final stage of septic shock. Sepsis diagnostics is the study of diagnosis of this condition.
North America is likely to dominate the sepsis diagnostics market during the forecast period. The US held the largest share of the North American market in 2021 and is expected to continue this trend during the forecast period. Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Increasing prevalence of sepsis and surging investments in the research and development of sepsis diagnosis are projected to accelerate the sepsis diagnostics market growth in the region. Moreover, the presence of large healthcare market players results in the growing sepsis diagnostics product launches.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Sepsis Diagnostics Market: Strategic Insights
Sepsis Diagnostics Market
-
CAGR (2021 - 2028)
9.2%
-
Market Size 2021
US$ 661.83 Million
-
Market Size 2028
US$ 1,226.52 Million
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Abbott
- F Hoffmann La Roche Ltd
- Immunexpress Inc
- BD
- Danaher
- Luminex Corporation
- Thermo Fisher Scientific Inc
- bioMerieux SA
- T2 Biosystems Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product
- Instruments
- Reagents and Assays
- Blood Culture Media
- Software
Technology
- Molecular Diagnostics
- Flow Cytometry
- Microfluidics
- Immunoassay
- Biomarker
- Microbiology
Method
- Automated Diagnostics and Conventional Diagnostics
Test Type
- Point-of-Care Tests and Laboratory Tests
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Sepsis Diagnostics Market: Strategic Insights
-
CAGR (2021 - 2028)9.2% -
Market Size 2021
US$ 661.83 Million -
Market Size 2028
US$ 1,226.52 Million
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Abbott
- F Hoffmann La Roche Ltd
- Immunexpress Inc
- BD
- Danaher
- Luminex Corporation
- Thermo Fisher Scientific Inc
- bioMerieux SA
- T2 Biosystems Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Instruments
- Reagents and Assays
- Blood Culture Media
- Software
- Molecular Diagnostics
- Flow Cytometry
- Microfluidics
- Immunoassay
- Biomarker
- Microbiology
- Automated Diagnostics and Conventional Diagnostics
- Point-of-Care Tests and Laboratory Tests
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The sepsis diagnostics report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, market dynamics, and the competitive analysis of the globally leading market players.
Market Insights
High Incidence of Sepsis due to Increasing Nosocomial Infections
Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Hospital-acquired infections, also known as nosocomial infections, are the primary cause of morbidity and mortality among hospitalized patients. According to the "2020 National and State Healthcare-Associated Infections Progress Report" published by the Centers for Disease Control and Prevention (CDC) in 2021, about 24%, 35%, and 15% increase was recorded in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia, respectively, in the US between 2019 and 2020. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products.
In September 2020, World Health Organization (WHO) estimated that each year almost 50% cases of sepsis are seen among children, and 2.9 million deaths occurred in children. Most deaths can be prevented through early diagnosis and appropriate clinical management. Thus, the high incidence rate of sepsis boosts the demand for sepsis diagnostic products, thereby supporting the sepsis diagnostics market growth.
Product Insights
Based on product, the global sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. In 2021, the blood culture media segment held the largest share of the market. According to the Journal of the Academy of Clinical Microbiologists report, blood culture media remains one of the most critical investigations in the sepsis management as it allows identification of the responsible organism for sepsis, appropriate choice of empirical and specific antibiotics, and points towards further investigations for identifying the focus on infection. A blood culture media is recommended for all septic patients. However, the software segment is anticipated to register the highest CAGR in the market during the forecast period.
Technology Insights
Based on technology, the global sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. In 2021, the microbiology segment held the largest share of the market. Rapid and specific pathogen identification is important for sepsis treatment, and microbiological techniques act as the gold standard for sepsis pathogen identification that can be done through blood culture followed by sub culturing and pathogen identification through biochemical or microscopic means. However, the molecular diagnostics segment is expected to register the highest CAGR in the market during forecast period.
Method Insights
Based on method, the global sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. In 2021, the conventional diagnostics segment held a larger share of the market. However, the automated diagnostics segment is expected to register a higher CAGR in the market during forecast period. Conventional diagnostics procedure for sepsis takes a few days. Thus, conventional diagnostics method is slowly adopted than automated diagnostics. Also, companies focus on developing automated diagnostics based on advanced technologies, such as molecular diagnostics for detecting sepsis.
Test Type Insights
Based on test type, the global sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. In 2021, the laboratory tests segment held a larger share of the market. However, the point-of-care tests segment is expected to register a higher CAGR in the market during forecast period. POC platforms can lead to timely intervention with appropriate therapeutics as it simplifies the needs of the diagnostics process by offering accessible and affordable clinical information to detect sepsis at a much earlier stage.
Pathogen Insights
Based on pathogen, the global sepsis diagnostics market is segmented into bacteria sepsis, fungal sepsis, and others. In 2021, the bacteria sepsis segment held the largest market share. Moreover, the same segment is expected to register the highest CAGR in the market during forecast period.
End User Insights
Based on end user, the global sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. In 2021, the hospitals segment held the largest share of the market. However, the pathology and reference laboratories segment is expected to register the highest CAGR in the market during forecast period.
Product launches and collaborations are highly adopted strategies by the global sepsis diagnostics market players to expand their global footprints and product portfolios. The players also focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally. They aim to flourish their market shares with the development of innovative products. A few of the recent key market developments are listed below:
- In November 2021, T2 Biosystems, Inc. executed territory exclusive distribution agreement in Taiwan. Under the terms of the agreement, T2 Biosystems will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance Panels through its distributor. T2 Biosystems and its new distribution partner are collaborated with the health authorities in Taiwan to gain regulatory approval and offer the highest quality sepsis care to patients.
- In May 2019, Danaher subsidiary Beckman Coulter launched Access PCT assay. The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time help physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes. The new Access PCT assay received CE mark certification and available for use on the Access Family of Immunoassay Systems, including the Access 2, UniCel DxI 600, and UniCel DxI 800.
Sepsis Diagnostics Market Report Scope
Report Attribute
Details
Market size in 2021
US$ 661.83 Million
Market Size by 2028
US$ 1,226.52 Million
Global CAGR (2021 - 2028)
9.2%
Historical Data
2019-2020
Forecast period
2022-2028
Segments Covered
By Product - Instruments
- Reagents and Assays
- Blood Culture Media
- Software
By Technology - Molecular Diagnostics
- Flow Cytometry
- Microfluidics
- Immunoassay
- Biomarker
- Microbiology
By Method - Automated Diagnostics and Conventional Diagnostics
By Test Type - Point-of-Care Tests and Laboratory Tests
Regions and Countries Covered
North America - US
- Canada
- Mexico
Europe - UK
- Germany
- France
- Russia
- Italy
- Rest of Europe
Asia-Pacific - China
- India
- Japan
- Australia
- Rest of Asia-Pacific
South and Central America - Brazil
- Argentina
- Rest of South and Central America
Middle East and Africa - South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
Market leaders and key company profiles
- Abbott
- F Hoffmann La Roche Ltd
- Immunexpress Inc
- BD
- Danaher
- Luminex Corporation
- Thermo Fisher Scientific Inc
- bioMerieux SA
- T2 Biosystems Inc
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 661.83 Million |
Market Size by 2028 | US$ 1,226.52 Million |
Global CAGR (2021 - 2028) | 9.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Sepsis Diagnostics – Market Segmentation
The global sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, and end user. In terms of product, the global sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. Based on technology, the sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. In terms of method, the market is segmented into automated diagnostics and conventional diagnostics. Based on test type, the global sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. In terms of pathogen, the market is segmented into bacteria sepsis, fungal sepsis, and others. In terms of end user, the sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others.
Company profile
- Abbott
- F. HOFFMANN-LA ROCHE LTD.
- Immunexpress Inc.
- BD
- Danaher
- Luminex Corporation
- Thermo Fisher Scientific Inc.
- bioMerieux SA.
- T2 Biosystems, Inc.
- Axis-Shield Diagnostics Ltd.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product, Technology, Method, Test Type, Pathogen, and End User
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The sepsis diagnostics market majorly consists of the players, such as Abbott; F. Hoffman-La Roche Ltd; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; Thermo Fischer Scientific Inc.; bioMerieux SA; T2 Biosystems, Inc.; Axis-Shield Diagnostics Ltd; among others.
The Centers for Disease Control and Prevention (CDC) defines sepsis as the body's extreme response to an infection. It is a life-threatening medical emergency. Sepsis can also be a result of other infections, including viral infections, such as COVID-19 or influenza. Early detection and specific clinical intervention has revealed to be crucial for improving the outcome of patients suffering from sepsis.
The factors that are driving the growth of market are high incidence of sepsis due to nosocomial infections and the high demand for rapid diagnostic tests leading to increasing product launches. However, the lack of skilled professionals is the major factor hindering the sepsis diagnostics market growth.
The market is estimated to grow at a CAGR of 9.2% during the forecast period.
The sepsis diagnostics market is analyzed in the basis of product, technology, method, test type, pathogen, and end user. Based on technology, the market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held the largest share of the market. However, the molecular diagnostics segment is anticipated to register the highest CAGR.
The sepsis diagnostics market is expected to be valued at US$ 1,226.52 million in 2028
The sepsis diagnostics market is estimated to be valued at US$ 661.83 million in 2021.
North America accounts for the major market share of sepsis diagnostics market in 2021 owing to rising number of product launches and approvals.
Asia Pacific is expected to be the fastest growing region in sepsis diagnostics market over the forecast period.
The List of Companies - Sepsis Diagnostics Market
- Abbott
- F. Hoffmann-La Roche Ltd.
- Immunexpress Inc.
- BD
- Danaher
- Luminex Corporation
- Thermo Fisher Scientific Inc.
- bioMerieux SA.
- T2 Biosystems, Inc.
- Axis-Shield Diagnostics Ltd.